{"data":[{"accessionNo":"0000919574-26-005493","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":1993837,"percentOfClass":3.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-005493","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":1993837,"percentOfClass":3.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-005493","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1993837,"percentOfClass":3.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001274173-26-000200","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS, INC.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"JANUS HENDERSON GROUP Ltd.","reportingCik":null,"personType":"HC","sharesOwned":172229,"percentOfClass":0.3,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0002012383-26-002544","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":4098457,"percentOfClass":6.7,"filedAt":"2026-07-28","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001274173-26-000148","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS, INC.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":4196409,"percentOfClass":6.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000093751-26-000251","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS INC","ticker":"JANX","cusip":"47103J105","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":2464017,"percentOfClass":4.1,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000315066-26-001219","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS INC","ticker":"JANX","cusip":"47103J105","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":2535723.63,"percentOfClass":4.2,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000315066-26-001219","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS INC","ticker":"JANX","cusip":"47103J105","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":2535723.63,"percentOfClass":4.2,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-002474","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-28","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":3069759,"percentOfClass":5,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-002475","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-28","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":3069759,"percentOfClass":5,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-002475","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-28","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":3069759,"percentOfClass":5,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-002475","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-28","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3069759,"percentOfClass":5,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-002474","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-28","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":3069759,"percentOfClass":5,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000919574-26-002474","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":"47103J105","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-04-28","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3069759,"percentOfClass":5,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001274173-26-000086","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS, INC.","ticker":"JANX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":5350453,"percentOfClass":8.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000093751-26-000058","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS INC","ticker":"JANX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":3853951,"percentOfClass":6.4,"filedAt":"2026-02-09","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001104659-26-011545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-02-03","reportingPerson":"W. Lawrence Hawkins","reportingCik":null,"personType":"HC,IN","sharesOwned":3157220,"percentOfClass":5.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001104659-26-011545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-02-03","reportingPerson":"Prosight Partners, LLC","reportingCik":null,"personType":"OO","sharesOwned":3150970,"percentOfClass":5.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001104659-26-011545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-02-03","reportingPerson":"Prosight Management, LP","reportingCik":null,"personType":"IA","sharesOwned":3150970,"percentOfClass":5.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001104659-26-011545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-02-03","reportingPerson":"Prosight Plus Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":685220,"percentOfClass":1.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001104659-26-011545","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001817713","issuerName":"Janux Therapeutics, Inc.","ticker":"JANX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-02-03","reportingPerson":"Prosight Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":148416,"percentOfClass":0.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000315066-26-000045","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS INC","ticker":"JANX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3512384,"percentOfClass":5.8,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0000315066-26-000045","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS INC","ticker":"JANX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3512384,"percentOfClass":5.8,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/janx"},{"accessionNo":"0001274173-25-000262","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001817713","issuerName":"JANUX THERAPEUTICS, INC.","ticker":"JANX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":6033949,"percentOfClass":10,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/janx"}],"updatedAt":"2026-11-04T00:37:23.461Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/janx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}